Introduction: The benefits of probiotics/prebiotics consumption on chronic kidney disease (CKD) and mortality remains controversial.
Objectives: This study investigates the association of probiotics/prebiotics consumption with chronic kidney disease (CKD) and mortality.
Methods: Clinical data were retrieved from the National Health and Nutrition Examination Survey (NHANES) 2005-2016 database.
Objectives: Existing systematic reviews related to advance care planning (ACP) largely focus on specific groups and intervention efficacy or are limited to contextual factors. This research aims to identify the modifiable factors perceived by different users of ACP in healthcare settings and inform healthcare professionals about the factors affecting ACP practice.
Methods: Five English-language databases (ProQuest, PubMed, CINAHL Plus, Scopus, and Medline) and two Chinese-language databases (CNKI and NCL) were searched up to November 2022.
Nephrology (Carlton)
November 2022
A retrospective study was conducted to evaluate the symptoms prevalence and interventions initiated in the last 2 weeks of life, health care service utilization, and causes of death of patients with end-stage renal disease (ESRD under a renal palliative care (RPC) program. A total of 335 RPC patients were included, of which 226 patients died during the study period. The 5 most prevalent symptoms were dyspnea (63.
View Article and Find Full Text PDFKidney transplant recipients have increased risk of cancers when compared with the general population. Hepatocellular carcinoma (HCC) is extremely important in Asia where hepatitis B virus (HBV) infection is endemic. The aim is to study the epidemiological and clinical aspects of all de novo HCC in our kidney transplant recipients.
View Article and Find Full Text PDFBackground: The response to recombinant hepatitis B vaccine remains suboptimal among the dialysis population.
Methods: In this multi-centre randomized controlled trial, we studied the factors that modify the response to intramuscular Engerix-B vaccination in patients on peritoneal dialysis. The primary aim was to study if a three-dose schedule of extra-high dose (80 microg) of Engerix-B would offer better primary seroconversion and more persistent serological protection than the conventional 40-microg dose.